Progress in immunotherapy for gastric cancer
10.3760/cma.j.issn.1673-9752.2010.04.003
- VernacularTitle:胃癌免疫治疗的新进展
- Author:
Yingjiang YE
;
Shan WANG
- Publication Type:Journal Article
- Keywords:
Gastric neoplasms;
Immunotherapy
- From:
Chinese Journal of Digestive Surgery
2010;09(4):247-249
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer is one of the most common malignancies in China. Currently, surgical resection, chemotherapy and radiotherapy are still the main therapeutic methods.The postoperative 5-year survival of patients with gastric cancer is lower than 60%. As a means of adjuvant therapy, immunotherapy has the potential to improve the survival of patients with gastric cancer, because its therapeutic targeting and toxicity profile does not overlap with those of conventional therapies. The effector cells of the immune system (T, B and NK cells), when activated, are able to lyse and destroy tumor cells through specific recognition of tumor-associated antigens. However, most immunotherapy research in gastric cancer is still limited to the preclinical stage due to the weakness of its antigenicity. With the development of tumor immunobiology and genetic engineering, immunotherapy has become the focus of research for the treatment of gastric cancer.
